

Kim A Margolin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4908279/publications.pdf>

Version: 2024-02-01

197
papers

21,895
citations

19608

61
h-index

9073

144
g-index

206
all docs

206
docs citations

206
times ranked

22673
citing authors

#	ARTICLE	IF	CITATIONS
1	Mac Cheever (1944â€“2021): a tribute to a life of achievement and service. , 2022, 10, e004433.		0
2	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptorâ€“positive breast cancer. JCI Insight, 2022, 7, .	2.3	17
3	Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report. Molecular and Clinical Oncology, 2021, 14, 46.	0.4	5
4	Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110422.	0.2	3
5	Tumor-infiltrating lymphocytes are associated with improved survival in node-positive Merkel cell carcinoma: A national cohort analysis. Journal of the American Academy of Dermatology, 2021, , .	0.6	2
6	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-Oncology, 2021, 23, 1961-1973.	0.6	66
7	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	1.7	2
8	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open, 2021, 6, 100252.	2.0	26
9	Unique challenges for glioblastoma immunotherapyâ€“discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	0.6	59
10	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 1692-1704.	5.1	129
11	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 2020, 183, 347-362.e24.	13.5	349
12	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	3.4	38
13	Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling. Annals of Surgical Oncology, 2020, 27, 5240-5247.	0.7	8
14	Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Reports, 2020, 6, 195-197.	0.4	13
15	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell and Melanoma Research, 2020, 33, 527-541.	1.5	36
16	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
17	And Now for Something Completely Different: Immunotherapy Beyond Checkpoints in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 386-397.	1.8	0
18	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 120-131.	2.3	11

#	ARTICLE	IF	CITATIONS
19	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
20	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
21	Cytokine Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 261-274.	0.9	24
22	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e59-e69.	1.8	8
23	Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-2.	0.2	1
24	Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019, 9, 581-583.	7.7	1
25	Reply to A. Shinde et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1031-1032.	0.8	0
26	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 693-702.	0.8	274
27	What is new on the horizon in melanoma brain metastasis?. <i>ESMO Open</i> , 2019, 4, e000579.	2.0	2
28	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	2.0	29
29	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 458-469.	1.5	31
30	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.	1.3	10
31	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2019, , 1-34.		0
32	Management of Metastatic Melanoma in 2018. <i>JAMA Oncology</i> , 2018, 4, 857.	3.4	26
33	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	5.1	87
34	Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 2177-2178.	13.9	15
35	NCI 8628: A randomized phase 2 study of zivâ€œflibercept and highâ€œdose interleukin 2 or highâ€œdose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	2.0	15
36	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. <i>Nature Communications</i> , 2018, 9, 4297.	5.8	101

#	ARTICLE	IF	CITATIONS
37	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
38	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 5552-5561.	3.2	150
39	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
40	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	3.2	34
41	After a treatment breakthroughâ€”progress, plateaus, and raising the bar. <i>Cancer</i> , 2017, 123, 2087-2088.	2.0	0
42	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOGâ€”ACRIN Cancer Research Group (E2607). <i>Cancer</i> , 2017, 123, 2688-2697.	2.0	103
43	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	1.3	183
44	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 641-650.	1.8	9
45	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 641-650.	1.8	8
46	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	0.6	209
47	Brain Metastases in Melanoma: Moving Toward Curing the Incurable. <i>Journal of Oncology Practice</i> , 2016, 12, 545-546.	2.5	2
48	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
49	Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade. <i>JAMA Oncology</i> , 2016, 2, 1186.	3.4	0
50	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	1.3	36
51	Disparate clinical activity of PDâ€”1 blockade in melanoma subtypes: Know thy enemy!. <i>Cancer</i> , 2016, 122, 3263-3266.	2.0	2
52	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	1.5	102
53	Combined IL-21â€”primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016, 213, 1133-1139.	4.2	78
54	T-Cell Therapy Using Interleukin-21â€”Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016, 34, 3787-3795.	0.8	98

#	ARTICLE	IF	CITATIONS
55	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	5.1	711
56	29th Annual meeting of the Society for Immunotherapy of Cancer (SITC). , 2015, 3, .		9
57	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 181-191.	1.4	20
58	Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain. <i>Seminars in Oncology</i> , 2015, 42, 459-465.	0.8	20
59	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinomaâ€”A Trial of the ECOGâ€”ACRIN Cancer Research Group (E2804). <i>Journal of Clinical Oncology</i> , 2015, 33, 2384-2391.	0.8	75
60	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>Journal of NeuroInterventional Surgery</i> , 2015, 7, e34-e34.	2.0	8
61	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
62	Phase 2 study of <sc>RO</sc>4929097, a gammaâ€”secretase inhibitor, in metastatic melanoma: <sc>SWOG</sc> 0933. <i>Cancer</i> , 2015, 121, 432-440.	2.0	80
63	The High-Dose Aldesleukin â€”Selectâ€”Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	3.2	133
64	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
65	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Groupâ€”American College of Radiology Imaging Network Cancer Research Group (E4697). <i>Journal of Clinical Oncology</i> , 2015, 33, 4066-4076.	0.8	101
66	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
67	Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 131-138.	0.1	5
68	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	2.3	9
69	Hemorrhagic collision metastasis in a cerebral arteriovenous malformation. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014011362-bcr2014011362.	0.2	2
70	A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 18-24.	1.0	43
71	Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. <i>Cancer</i> , 2014, 120, 1617-1619.	2.0	30
72	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 56-67.	1.2	234

#	ARTICLE	IF	CITATIONS
73	Introduction to the Role of the Immune System in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 537-558.	0.9	8
74	Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182.	2.3	56
75	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	5.1	116
76	Cytokines in the Treatment of Cancer. , 2013, , 173-210.		1
77	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598.	12.5	177
78	Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 121-127.	0.9	7
79	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i> , 2013, 8, 479-487.	0.3	4
80	A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2013, 36, 490-495.	1.2	25
81	Multidisciplinary Approach to Brain Metastasis from Melanoma; Local Therapies for Central Nervous System Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 399-403.	1.8	18
82	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 393-398.	1.8	22
83	Multidisciplinary Approach to Brain Metastasis from Melanoma; Local Therapies for Central Nervous System Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 399-403.	1.8	26
84	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 393-398.	1.8	24
85	Ipilimumab in a Phase II trial of melanoma patients with brain metastases. <i>Oncolmmunology</i> , 2012, 1, 1197-1199.	2.1	39
86	Randomized Phase II Trial of Sorafenib with Teme sirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438). <i>Clinical Cancer Research</i> , 2012, 18, 1129-1137.	3.2	86
87	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 502-535.	2.3	71
88	BRAF inhibition and beyond in advanced melanoma. <i>Lancet</i> , The, 2012, 380, 320-322.	6.3	5
89	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 459-465.	5.1	995
90	Ipilimumab in patients with melanoma and brain metastases – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e277-e278.	5.1	3

#	ARTICLE	IF	CITATIONS
91	Tumor-Infiltrating Lymphocytes in Melanoma. <i>Current Oncology Reports</i> , 2012, 14, 468-474.	1.8	82
92	Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512. <i>PLoS ONE</i> , 2012, 7, e48787.	1.1	77
93	Transferred melanoma-specific CD8 ⁺ T cells persist, mediate tumor regression, and acquire central memory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4592-4597.	3.3	142
94	An open-label, phase 2 trial of RPL4610 (angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012, 118, 4098-4104.	2.0	33
95	A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. <i>Investigational New Drugs</i> , 2012, 30, 741-748.	1.2	52
96	Targeting the mTOR, PI3K, and AKT Pathways in Melanoma. , 2012, , 107-123.		0
97	NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-29.	2.3	48
98	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 960-977.	2.3	90
99	A phase II trial of gefitinib and pegylated IFN γ in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011, 16, 494-9.	1.0	9
100	Treatment of Advanced Melanoma with Immunological Checkpoint Block. <i>Current Oncology Reports</i> , 2011, 13, 430-432.	1.8	2
101	Adoptive T-Cell Therapy of Melanoma Using Designer T-Cell Receptors. <i>Current Oncology Reports</i> , 2011, 13, 427-429.	1.8	1
102	Melanoma's deadly march to the brain. <i>Cancer</i> , 2011, 117, 1560-1563.	2.0	3
103	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. <i>Clinical Cancer Research</i> , 2011, 17, 6574-6581.	3.2	77
104	Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. <i>Journal of Clinical Oncology</i> , 2011, 29, 2178-2184.	0.8	226
105	Cytokines in Cancer Immunotherapy. <i>Cancers</i> , 2011, 3, 3856-3893.	1.7	549
106	Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 927-933.	1.1	14
107	Indoor Tanning and Substance-Related Disorder—Related Behaviors With Similar Treatment?. <i>Current Oncology Reports</i> , 2010, 12, 288-289.	1.8	0
108	Indoor Tanning Use Among U.S. Youth—Can Skin Health Behaviors be Legislated?. <i>Current Oncology Reports</i> , 2010, 12, 290-291.	1.8	1

#	ARTICLE	IF	CITATIONS
109	Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy. <i>Seminars in Oncology</i> , 2010, 37, 468-472.	0.8	33
110	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4906-4911.	0.8	267
111	Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery. <i>Journal of Clinical Oncology</i> , 2010, 28, 1196-1202.	0.8	19
112	Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2163-2169.	0.8	59
113	IL-2 in the therapy of melanoma and other malignancies. <i>Medical Oncology</i> , 2009, 26, 23-31.	1.2	0
114	Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. <i>Current Oncology Reports</i> , 2009, 11, 405-411.	1.8	9
115	CCR9:CCL25 in melanoma metastatic to small intestine. <i>Current Oncology Reports</i> , 2009, 11, 331-332.	1.8	0
116	Control of experimental melanoma by host CXCR2. <i>Current Oncology Reports</i> , 2009, 11, 333-334.	1.8	0
117	Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1149-1155.	1.1	11
118	Summary of the primer on tumor immunology and the biological therapy of cancer. <i>Journal of Translational Medicine</i> , 2009, 7, 11.	1.8	9
119	Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 618-630.	2.3	249
120	Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 672-693.	2.3	103
121	State of the science 60th anniversary review. <i>Cancer</i> , 2008, 113, 1728-1743.	2.0	14
122	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. <i>Cancer</i> , 2008, 113, 2139-2145.	2.0	77
123	Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. <i>Community Oncology</i> , 2008, 5, 367-374.	0.2	7
124	Cytokine therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1495-1505.	1.4	27
125	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3743-3748.	0.8	381
126	Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2292-2298.	0.8	103

#	ARTICLE	IF	CITATIONS
127	Melanoma and Other Cutaneous Malignancies. , 2008, , 2037-2059.		0
128	Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity. <i>Clinical Cancer Research</i> , 2007, 13, 1232-1237.	3.2	35
129	An Introduction to Foundation and Industry-Sponsored Research: Practical and Ethical Considerations. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 498-503.	0.9	4
130	Shortening the Infusion Time of Anticancer Drugs: Who Will Benefit?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2642-2643.	0.8	1
131	Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 247-256.	0.8	326
132	Phase I Trial of BAY 50-4798, an Interleukin-2â€“Specific Agonist in Advanced Melanoma and Renal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3312-3319.	3.2	44
133	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study. <i>Journal of Immunotherapy</i> , 2007, 30, 839-846.	1.2	6
134	Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides. <i>Journal of Immunotherapy</i> , 2007, 30, 762-772.	1.2	89
135	Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 178, 1883-1887.	0.2	186
136	A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 549-557.	1.1	4
137	Oblimersen and Î±-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 705-711.	1.2	13
138	Interleukin-2 and Cancer Therapy. , 2007, , 307-316.		1
139	A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 57-60.	0.9	140
140	Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 778-785.	2.0	40
141	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006, 106, 2624-2629.	2.0	33
142	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.	3.8	1,111
143	CCI-779 in metastatic melanoma. <i>Cancer</i> , 2005, 104, 1045-1048.	2.0	245
144	Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. <i>Investigational New Drugs</i> , 2005, 23, 235-239.	1.2	39

#	ARTICLE	IF	CITATIONS
145	Management of Advanced Germ Cell Cancer in Patients With Unfavorable Prognosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 77-83.	2.3	1
146	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	0.8	746
147	Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 903-911.	2.0	26
148	Mitotic rate and younger age as predictors of sentinel lymph node positivity. <i>Current Oncology Reports</i> , 2005, 7, 375, 376.	1.8	1
149	Molecular staging in stage II and III melanoma patients. <i>Current Oncology Reports</i> , 2005, 7, 376.	1.8	0
150	Prognostic Indicators and Survival in Patients With Stage IIIB Inflammatory Breast Carcinoma After Dose-Intense Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1839-1848.	0.8	60
151	Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel. <i>Clinical Cancer Research</i> , 2004, 10, 461-467.	3.2	73
152	Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96Åh for the treatment of advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 241-248.	1.1	7
153	Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 283-289.	1.1	9
154	A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 331-42.	1.1	76
155	Biochemotherapy for melanoma. <i>Cancer</i> , 2004, 101, 435-438.	2.0	24
156	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. <i>Blood</i> , 2004, 104, 810-810.	0.6	5
157	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. Relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. <i>Journal of Clinical Laboratory Analysis</i> , 2003, 17, 184-194.	0.9	13
158	High Dose Chemotherapy and Stem Cell Support in the Treatment of Germ Cell Cancer. <i>Journal of Urology</i> , 2003, 169, 1229-1233.	0.2	11
159	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	0.8	307
160	The treatment of brain metastases from malignant melanoma. <i>Seminars in Oncology</i> , 2002, 29, 518-524.	0.8	88
161	Inhibition of vascular endothelial growth factor in the treatment of solid tumors. <i>Current Oncology Reports</i> , 2002, 4, 20-28.	1.8	26
162	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 353-359.	1.1	9

#	ARTICLE	IF	CITATIONS
163	Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 214-218.	1.2	134
164	Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 284-293.	2.0	6
165	Methodologic guidelines for the design of high-dose chemotherapy regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 414-432.	2.0	19
166	Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data. <i>Journal of Clinical Oncology</i> , 2001, 19, 851-856.	0.8	365
167	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 327-332.	1.1	9
168	Autologous and allogeneic high-dose therapy for melanoma. <i>Current Oncology Reports</i> , 2001, 3, 338-343.	1.8	2
169	Dolastatin-10 in metastatic melanoma: a phase II and pharmacokinetic trial of the California Cancer Consortium. <i>Investigational New Drugs</i> , 2001, 19, 335-340.	1.2	74
170	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part I. IL-2-Based Clinical Trials. <i>Medical Oncology</i> , 2001, 18, 197-208.	1.2	27
171	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part II: Management of IL-2 Toxicity and Studies with Other Cytokines. <i>Medical Oncology</i> , 2001, 18, 209-220.	1.2	40
172	Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up. <i>Gynecologic Oncology</i> , 2000, 77, 433-438.	0.6	20
173	Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 19-26.	1.1	93
174	A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 403-410.	1.1	8
175	Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 46-54.	2.1	49
176	Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy. <i>Blood</i> , 1999, 93, 2798-2806.	0.6	90
177	Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term Follow-Up. <i>Gynecologic Oncology</i> , 1999, 75, 419-426.	0.6	8
178	Phase II trial of biochemotherapy with interferon α , dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 292-296.	1.2	12
179	Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 36-45.	2.0	20
180	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999, 17, 2105-2105.	0.8	1,810

#	ARTICLE	IF	CITATIONS
181	Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group. <i>Blood</i> , 1997, 90, 3844-3852.	0.6	93
182	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997, 157, 231-240.	2.8	44
183	A Phase II Study of the Continuous Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 1995, 18, 52-56.	1.2	19
184	Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. <i>Investigational New Drugs</i> , 1995, 13, 157-162.	1.2	48
185	Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 103-106.	1.2	36
186	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 293-298.	1.1	38
187	Phase I study of mitomycin C and menadione in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 293-298.	1.1	3
188	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994, 73, 125-134.	2.0	34
189	High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994, 73, 1678-1685.	2.0	47
190	Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 35, 161-164.	1.1	4
191	Immunotherapy of Colorectal Cancer. <i>BioDrugs</i> , 1994, 2, 42-52.	0.7	0
192	Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. <i>Journal of Immunotherapy</i> , 1994, 15, 147-153.	1.2	58
193	High-risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. <i>Cancer</i> , 1993, 71, 2351-2357.	2.0	9
194	The unique association of malignant histiocytosis and a primary gonadal germ cell tumor. <i>Medical and Pediatric Oncology</i> , 1992, 20, 162-164.	1.0	12
195	Treatment of metastatic malignant melanoma with trimetrexate: A phase II study. <i>Medical and Pediatric Oncology</i> , 1990, 18, 49-52.	1.0	6
196	High-titer, High-thermal-amplitude Cold Autoagglutinin Not Associated with Hemolytic Anemia. <i>Vox Sanguinis</i> , 1988, 55, 26-29.	0.7	8
197	Hepatic metastasis in granulosa cell tumor of the ovary. <i>Cancer</i> , 1985, 56, 691-695.	2.0	38